Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia

Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia
  • The European Commission has approved Sanofi SA SNY Enjaymo (sutimlimab) for hemolytic anemia in adult patients with cold agglutinin disease (CAD).
  • CAD is a rare chronic autoimmune hemolytic anemia, where the body's immune system mistakenly attacks healthy red blood cells, rupturing them (hemolysis).
  • Related: Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster.
  • Enjaymo is currently the only approved treatment for CAD. It is a first-in-class humanized monoclonal antibody designed to selectively target and inhibit the classical complement pathway-specific serine protease, C1s. 
  • The approval is based on data from two Phase 3 trials - CADENZA and CARDINAL.
  • In the CADENZA Part A study, Enjaymo met its primary composite endpoint and all secondary endpoints. It demonstrated hemolysis inhibition, hemoglobin levels increase, and clinically meaningful improvement in Fatigue scores. 
  • Also Read: Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook.
  • Price Action: SNY shares are up 0.18% at $43.94 on the last check Thursday.

Posted In: BriefsEuropean Medicines AgencyBiotechLarge CapNewsHealth CareGeneral